Enjoy complimentary customisation on priority with our Enterprise License!
The phage therapy market size is forecast to increase by USD 51 million, at a CAGR of 17.41% between 2023 and 2028.
Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample
The phage therapy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The escherichia coli segment is estimated to witness significant growth during the forecast period.
Phage therapy, an alternative approach to combating antibiotic-resistant bacteria, has gained significant attention in the healthcare industry due to the increasing threat of infectious diseases caused by antibiotic-resistant strains. Lytic phages, viruses that kill bacteria, have emerged as potential solutions to treat various bacterial infections, including those caused by Escherichia coli. Phage dynamics, such as specificity, administration, resistance, and engineering, are crucial factors in the development of effective phage therapies. Phage proteomics, genomic analysis, and bioinformatics have advanced our understanding of phage-bacterial interactions, enabling the design of targeted phage therapies. Phage libraries and biopanning techniques facilitate the isolation and selection of phages with high efficacy against specific bacterial strains.
Phage cocktails, consisting of multiple phages, offer broader coverage against various bacterial strains and reduce the risk of resistance development. Phage therapy has shown promise in treating hospital-acquired infections, wound infections, and biofilm-associated infections. Clinical trials are underway to evaluate the safety and efficacy of phage therapies for intravenous and oral administration. Phage-based bioremediation and biocontrol applications are also being explored for environmental and agricultural applications. Phage resistance and safety concerns are being addressed through the development of phage formulations and engineering strategies. Phage-based diagnostics are being developed to aid in the rapid identification and treatment of bacterial infections.
Multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE), pose a significant challenge to conventional antibiotic treatments. Phage therapy offers a potential solution to these antibiotic-resistant bacteria, making it a promising area of research and development.
The Escherichia coli segment was valued at USD 9.62 million in 2018 and showed a gradual increase during the forecast period.
Europe is estimated to contribute 34% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Europe's the market experiences significant growth due to several factors. Notable contributors to this market are Germany and the UK, driven by the presence of top-tier healthcare providers and patient care services, advanced healthcare infrastructure, substantial investments in the healthcare sector, and government backing for research initiatives. In 2023, high Tuberculosis (TB) detection rates were reported in Europe, leading to a surge in the adoption of phage therapy for drug-resistant TB strains.
Major players like Micreos, APS Biocontrol, and Nexabiome, with a strong presence in the region, further fuel market expansion.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The market encompasses the development, production, and application of bacteriophages, or phages, for therapeutic purposes. These viruses naturally target and destroy bacteria, offering an alternative to traditional antibiotics in addressing antibiotic-resistant infections. Phage therapy holds promise for various applications, including wound care, food safety, and animal health. Technological advancements, such as genetic engineering and nanotechnology, are driving innovation in phage therapy, enabling the creation of more effective and targeted phage therapies. End-users, including healthcare providers and researchers, seek safe, efficient, and cost-effective solutions to combat antibiotic-resistant bacteria, further fueling market growth. Phages exhibit broad spectrum antimicrobial activity, making them valuable in treating multi-drug resistant infections. The adaptive nature of bacteria, however, necessitates continuous research and development to ensure the long-term efficacy of phage therapies. Phage display, a key technology, facilitates the identification and production of effective phages, streamlining the therapeutic development process. Phage cocktails, consisting of multiple phages, provide a synergistic effect against bacterial infections. Phage therapy holds potential for various industries, including pharmaceuticals, biotechnology, and food processing, making it a dynamic and evolving market.
ai_test_driver_explanation_gai.multili
The phage therapy market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the phage therapy market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, phage therapy market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Adaptive Phage Therapeutics (United States) - Phage therapy, a novel approach in microbial infection treatment, includes PT phage bank therapy suitable for laboratory applications. This method leverages bacteriophages, viruses that target and eliminate specific bacteria, to combat microbial growth. By utilizing a diverse phage bank, this therapy offers potential advantages in combating antibiotic-resistant strains. Laboratories can benefit from this innovative solution, enhancing their research capabilities and contributing to advancements in microbiology. Phage therapy presents a promising alternative to traditional antibiotic treatments, offering a unique and original approach to microbial infection management.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses the use of bacteriophages, or phages, as an alternative approach to combating antibiotic-resistant bacteria. Phages are viruses that specifically target and infect bacteria, offering a potential solution to the global health threat posed by antibiotic-resistant strains of microorganisms. Several bacterial pathogens, including Ureaplasma urealyticum, Streptococcus pneumoniae, Clostridium difficile, Escherichia coli, Borrelia burgdorferi, Chlamydia trachomatis, Helicobacter pylori, Orienta tsutsugamushi, Mycobacterium tuberculosis, Bacteroides fragilis, Francisella tularensis, Salmonella enterica, Anaplasma phagocytophilum, Burkholderia cepacia, Shigella dysenteriae, Pseudomonas aeruginosa, Bacillus anthracis, Rickettsia rickettsii, Staphylococcus aureus, Listeria monocytogenes, Brucella abortus, Vibrio cholerae, Acinetobacter baumannii, Neisseria gonorrhoeae, Leptospira interrogans, Campylobacter jejuni, Yersinia enterocolitica, Haemophilus influenzae, Yersinia pestis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Ehrlichia chaffeensis, and Treponema pallidum, are targets for phage therapy research and development.
Market trends indicate a growing interest in this field, with increased funding and collaborations between academic institutions and industry players. The potential for personalized phage therapy, which involves the isolation and cultivation of phages specific to an individual's bacterial infection, adds to the market's appeal. Phages offer a promising alternative to traditional antibiotics, with the potential to revolutionize the way we treat bacterial infections.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Phage Therapy Market insights. See full methodology.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
156 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 17.41% |
|
Market growth 2024-2028 |
USD 51 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
14.43 |
|
Key countries |
US, Canada, Poland, UK, China, India, France, Japan, Netherlands, South Korea, UAE, and Brazil |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
We can help! Our analysts can customize this phage therapy market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Market Segmentation by By Route of Administration
9 Market Segmentation by By Disease Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
14 Competitive Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
